Andrea De Luca

Summary

Country: Italy

Publications

  1. doi request reprint Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy
    Genny Meini
    Department of Medical Biotechnologies, University of Siena, Siena, Italy
    J Antimicrob Chemother 69:735-41. 2014
  2. pmc The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study
    Andrea De Luca
    University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy
    BMC Infect Dis 13:414. 2013
  3. doi request reprint Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:113-20. 2012
  4. doi request reprint Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries
    Andrea De Luca
    Department of Internal and Specialty Medicine, University Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
    J Infect Dis 207:S63-9. 2013
  5. doi request reprint Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
    Andrea De Luca
    Catholic University of the Sacred Heart, Rome, Italy
    J Infect Dis 207:1216-20. 2013
  6. doi request reprint Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:236-44. 2012
  7. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
  8. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
  9. ncbi request reprint Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
    Clin Infect Dis 40:e101-9. 2005
  10. ncbi request reprint Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:743-52. 2004

Collaborators

Detail Information

Publications59

  1. doi request reprint Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy
    Genny Meini
    Department of Medical Biotechnologies, University of Siena, Siena, Italy
    J Antimicrob Chemother 69:735-41. 2014
    ..The aim of this study was to compare HIV-1 tropism as detected in baseline plasma RNA and peripheral blood mononuclear cell (PBMC) DNA prior to first-line therapy and to analyse tropism evolution while on successful treatment...
  2. pmc The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study
    Andrea De Luca
    University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy
    BMC Infect Dis 13:414. 2013
    ..Aim of the study was to evaluate whether hsCRP or other biomarkers are independent predictors of CVD risk in HIV-infected patients...
  3. doi request reprint Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:113-20. 2012
    ..63, P = 0.11; cause-specific aRR 5.27, P = 0.019) than those with haplogroup H. Mitochondrial haplogroups may explain part of the genetic predisposition to lipodystrophy during combination antiretroviral therapy...
  4. doi request reprint Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries
    Andrea De Luca
    Department of Internal and Specialty Medicine, University Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
    J Infect Dis 207:S63-9. 2013
    ..Rational use of resources, including broader access to viral load monitoring, will help ensure 3 lines of fully active treatment options, thereby increasing the duration of ART success...
  5. doi request reprint Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
    Andrea De Luca
    Catholic University of the Sacred Heart, Rome, Italy
    J Infect Dis 207:1216-20. 2013
    ..5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis...
  6. doi request reprint Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 59:236-44. 2012
    ..We investigated the prognostic value of virological and immunological status 6 months after ART initiation with respect to death, loss to follow-up, and treatment switch...
  7. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
    ..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort...
  8. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
    ..To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression on a stable atazanavir/ritonavir-based standard triple regimen...
  9. ncbi request reprint Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals
    Giorgio Antonucci
    National Institute of Infectious Diseases, L Spallanzani, Rome, Italy
    Clin Infect Dis 40:e101-9. 2005
    ..We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype...
  10. ncbi request reprint Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:743-52. 2004
    ..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)...
  11. ncbi request reprint Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:583-93. 2004
    ....
  12. ncbi request reprint Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 11:609-18. 2006
    ..A multi-cohort prospective observational comparative study was performed...
  13. ncbi request reprint Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 14:359-69. 2009
    ..This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA)...
  14. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  15. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
    ..The achievement of virological suppression is a strong predictor of reduced clinical progression...
  16. doi request reprint Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Med Virol 82:1996-2003. 2010
    ..Despite the likely differences in patient population and adherence, both the low rate of virological failure and the lack of development of LPV/rtv resistance documented in clinical trials are thus confirmed in clinical practice...
  17. ncbi request reprint Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
    ..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir...
  18. ncbi request reprint Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 8:51-6. 2003
    ..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment...
  19. doi request reprint Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 16:489-97. 2011
    ..There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score...
  20. ncbi request reprint Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
    Laura Bracciale
    Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    Antivir Ther 14:99-101. 2009
    ....
  21. ncbi request reprint Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Scand J Infect Dis Suppl 106:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...
  22. doi request reprint Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Opin HIV AIDS 5:27-37. 2010
    ..Knowledge of the prevalence of transmitted and emerging drug resistance as well as its specific patterns is of help in guiding the selection of appropriate ART types and sequencing strategies...
  23. ncbi request reprint Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Policlinoco Universitario Agostino Gemelli, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
    J Acquir Immune Defic Syndr 45:411-7. 2007
    ..The extent to which HIV-1 replication capacity (RC) influences the response to therapy remains to be established...
  24. doi request reprint Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Antimicrob Chemother 66:1886-96. 2011
    ....
  25. ncbi request reprint Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Antivir Ther 11:321-7. 2006
    ....
  26. pmc A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
    BMC Med Inform Decis Mak 11:40. 2011
    ..However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed...
  27. ncbi request reprint Clinical implications of HIV-1 drug resistance in the neurological compartment
    Andrea Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    Scand J Infect Dis Suppl 106:41-4. 2003
    ....
  28. ncbi request reprint Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    J Acquir Immune Defic Syndr 35:359-66. 2004
    ..When these drugs are coadministered, therapeutic drug monitoring should be employed and the IQ can be used to determine target drug levels...
  29. pmc Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
    ..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)...
  30. ncbi request reprint Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Neurovirol 13:338-46. 2007
    ..To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis...
  31. doi request reprint Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Lazio Region, Rome, Italy
    AIDS 22:1759-67. 2008
    ..To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy...
  32. doi request reprint Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting
    Maurizio Zazzi
    Department of Molecular Biology, University of Siena, Siena, Italy
    J Antimicrob Chemother 64:616-24. 2009
    ..To test retrospectively the ability of four freely available rules-based expert systems to predict short- and medium-term virological outcome following an antiretroviral treatment switch in pre-treated HIV-1 patients...
  33. ncbi request reprint Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 187:1934-43. 2003
    ..GSSs predicted changes in HIV RNA levels better in adherent patients than in nonadherent individuals. Interpretation may be improved, and knowledge should be used uniformly throughout different expert systems...
  34. doi request reprint Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1
    Carmela Pinnetti
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 15:127-9. 2010
    ..The analysis of darunavir/ritonavir concentrations in peripheral maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed low levels of darunavir in the mother and limited transfer across the placenta...
  35. doi request reprint Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Antimicrob Chemother 64:109-17. 2009
    ....
  36. doi request reprint Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy
    Ilaria Vicenti
    Department of Biotechnology, University of Siena, Siena, Italy
    J Antimicrob Chemother 67:984-7. 2012
    ..To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resistance mutations in HCV genotype 1-infected PI-naive individuals in Italy...
  37. doi request reprint Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition
    Antonella Cingolani
    Catholic University, Roma, Italy
    Clin Infect Dis 54:853-61. 2012
    ..The impact of human immunodeficiency virus (HIV)-associated tuberculosis on CD4 T-cell count response to combined antiretroviral therapy (cART) is poorly investigated...
  38. pmc The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
    PLoS ONE 5:e13619. 2010
    ..We introduce the threshold bootstrap clustering (TBC), a new methodology for partitioning molecular sequences, that does not require a phylogenetic tree estimation...
  39. doi request reprint Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Pharmacol Res 63:249-53. 2011
    ..In conclusion, a potential drug interaction between darunavir and raltegravir was observed, although this did not seem virologically significant. For the distinct metabolic pathways of these drugs, its mechanism remains to be determined...
  40. doi request reprint The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011
    ..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions...
  41. ncbi request reprint Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Arch Intern Med 162:2125-32. 2002
    ..The effect of chronic coinfection with hepatitis viruses on the response to therapy against human immunodeficiency virus 1 (HIV-1) remains debated...
  42. doi request reprint Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia
    Nicoletta Ciccarelli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 18:153-60. 2013
    ..The objective of our study was to compare two different central nervous system penetration-effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients...
  43. ncbi request reprint Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability
    Leonardo Palombi
    Department of Public Health, University Tor Vergata, Catholic University, Rome, Italy
    Clin Infect Dis 48:115-122. 2009
    ..Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortality and loss to follow-up. Switching to second-line regimens is often delayed because of limited access to laboratory monitoring...
  44. ncbi request reprint Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens
    Maria Paola Trotta
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Rome, Italy
    AIDS 17:1099-102. 2003
    ..By contrast, younger age, self-report of active drug use, fatigue or vomiting negatively affected adherence. Self-reported sexual dysfunction was significantly associated with non-adherence only in PI-treated individuals...
  45. ncbi request reprint Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy
    Andrea De Luca
    Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 193:1219-22. 2006
    ..42 [95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [95% CI, 1.04-1.75])...
  46. ncbi request reprint Virologic correlates of adherence to antiretroviral medications and therapeutic failure
    Carlo Federico Perno
    INMI L Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 31:S118-22. 2002
    ....
  47. doi request reprint A novel methodology for large-scale phylogeny partition
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Nat Commun 2:321. 2011
    ..Our method takes an advantage of a flexible notion of transmission cluster and can become a general framework to analyse other epidemics...
  48. ncbi request reprint Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of of Sacred Heart, Rome, Italy
    AIDS 18:1602-4. 2004
    ..Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals...
  49. doi request reprint Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
    Vaccine 29:2836-9. 2011
    ..These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients...
  50. doi request reprint Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization
    Mattia C F Prosperi
    Department of Computer Science and Automation, University of Roma Tre, Informa Contract Research Organisation, Infectious Disease Clinic, Catholic University of Sacred Heart, Rome, Italy
    Bioinformatics 25:1040-7. 2009
    ..The effect of limited adherence to therapy was also analyzed. Sequential treatment change episodes were also exploited with the aim to evaluate optimal synoptic treatment scenarios...
  51. doi request reprint Predictors of adverse outcomes in HIV-1-infected children receiving combination antiretroviral treatment: results from a DREAM cohort in sub-Saharan Africa
    Maria Cristina Marazzi
    From the Department of Preventive Medicine, LUMSA University Libera Università Maria SS Assunta DREAM Program Department of Biomedicine and Prevention, Tor Vergata University, Via Montpellier, Rome, Italy Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA Azienda Ospedaliedra Universitaria Senese, Siena Università Cattolica Sacro Cuore, Rome, Italy and DREAM Program Mozambique, Maputo, Mozambique
    Pediatr Infect Dis J 33:295-300. 2014
    ..HIV-infected children have less access to combination antiretroviral therapy as compared with adults in resource-limited settings. Growth faltering, loss to follow-up (LTFU) and high mortality are frequently seen...
  52. ncbi request reprint Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort
    Antonella Cingolani
    Department of Public Health, Institute of Infectious Diseases, Catholic University, Roma, Italy
    PLoS ONE 9:e89861. 2014
    ..Objectives of this study were to evaluate if in patients diagnosed with ADE the time to ART initiation may vary according to year of diagnosis and type of ADE...
  53. doi request reprint Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120
    Lucia Lisi
    Institute of Pharmacology, Catholic University Medical School, Rome, Italy
    J Neurochem 120:106-14. 2012
    ..In this experimental paradigm, maraviroc significantly increased microglial activation, thus suggesting that its chronic use can exacerbate neuronal pathology, especially in HIV-experienced patients with higher cerebral IFNγ levels...
  54. doi request reprint Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR
    Cinzia Dello Russo
    Institute of Pharmacology, Catholic University Medical School, Rome, Italy
    Pharmacogenomics 12:567-76. 2011
    ..A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study...
  55. ncbi request reprint Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Tor Vergata University, Rome, Italy
    Curr Opin Infect Dis 16:573-80. 2003
    ....
  56. ncbi request reprint An outbreak of HIV-1 subtype G among Italian injecting drug users
    Massimo Ciccozzi
    Epidemiology Unit, Department of Infectious, Parasite and Immune mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
    AIDS 21:1213-5. 2007
    ..All G subtypes but one were found among IDU. The phylogenetic analysis indicated that the outbreak was of monophyletic origin and was caused by HIV-1 strains similar to those from western Africa...
  57. ncbi request reprint HCMV infection in renal transplant recipients: a retrospective cohort study
    Camilla Puttini
    Infectious Diseases Section, Department of Medical Biotechnologies, University Hospital, Siena, Italy
    New Microbiol 36:363-71. 2013
    ..The choice of different immunosuppressive strategies might be associated with HCMV replication...
  58. ncbi request reprint Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 68:479-88. 2002
    ..In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV...
  59. ncbi request reprint Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia
    Federica Sora
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    Exp Hematol 30:279-84. 2002
    ..To evaluate the safety, feasibility, and efficacy of allogeneic stem cell transplantation (SCT) for acute myelogenous leukemia (AML) in a young female coinfected by HIV and HCV undergoing highly active antiretroviral therapy (HAART)...